Unified clinical trial software
Unified clinical trial software for hematology clinical trials
oomnia helps streamline hematology trials by connecting clinical data and workflows across studies advancing treatments for blood disorders and hematologic malignancies.
INDUSTRY CONTEXT
Why hematology trials are challenging to run
Hematology trials involve highly variable diseases, evolving treatment approaches, and intensive monitoring requirements that place unique demands on study design and execution
Key challenges include:
Heterogeneous patient populations, with wide variability in disease subtype, severity, genetics, and prior treatments
Evolving protocols and endpoints, driven by emerging science, changing standards of care, and response‑based treatment adjustments
Complex data requirements, including longitudinal lab values, transfusion data, safety monitoring, and disease response assessments
Extended study durations, often requiring long‑term follow‑up to assess durability of response, survival outcomes, or relapse
High operational and site burden, as frequent assessments and safety checks must be balanced with strict data quality and compliance expectations
UNIFIED PLATFORM
Why unified clinical trial software matters for hematology studies
Hematology trials involve repeated laboratory assessments, continuous safety monitoring, and long‑term tracking of patient outcomes across diverse blood diseases. When clinical data, lab results, and operational workflows are spread across separate systems, teams face delays, inconsistencies, and a heavy reconciliation burden.
A unified clinical trial platform, built as a Clinical Research Information System (CRIS), brings hematology trial operations and data into one coordinated environment.
This approach enables consistent data capture, stronger oversight, and real‑time visibility across hematology studies, supporting accurate decision‑making in trials where every assessment and data point matters.
| Area | Modular eClinical system | Unified clinical trial software (oomnia) |
|---|---|---|
| Data types | Laboratory results, safety data, clinical outcomes, and patient‑reported data stored in separate systems | All hematology trial data managed within one CRIS |
| Data consistency | Variation across sites, labs, and assessment schedules | Standardized data capture across all study components |
| Reconciliation | Manual alignment of lab, clinical, and safety data | Reduced reconciliation through a shared data model |
| Patient monitoring | Delayed insight into response, relapse, or adverse events | Real‑time visibility into longitudinal patient outcomes |
| Study execution | Disconnected workflows across sponsors, sites, and labs | Coordinated workflows across the full hematology ecosystem |
| Data quality | Increased risk of missing or inconsistent data over long timelines | Structured data capture with built‑in validation checks |
| Oversight | Fragmented study visibility across data sources | Unified oversight across clinical, lab, and safety data |
| Scalability | Difficult to manage long‑running and lab‑intensive studies | Designed to support multi‑site, long‑duration hematology trials |
CRIS ARCHITECTURE
One unified clinical trial platform for hematology studies
For hematology trials challenged by repeated lab testing, extended follow‑up, and protocol changes, oomnia provides one Clinical Research Information System (CRIS) that keeps study data and operations aligned
Handles frequent and variable laboratory assessments by unifying longitudinal lab values, transfusion data, and safety monitoring in one CRIS, reducing manual tracking across systems
Reduces site burden caused by repeated visits and assessments through streamlined workflows that minimize duplicate data entry and simplify coordination
Enables long‑term outcome tracking within the same system, supporting studies that require extended follow‑up for relapse, survival, or durability of response
Improves oversight in data‑intensive studies by giving sponsors real‑time visibility into safety signals, missing data, and operational status across sites
ECOSYSTEM INTEGRATION
How oomnia supports the hematology clinical trial ecosystem
oomnia helps hematology sponsors coordinate sites, labs, safety teams, and data systems by bringing the full trial ecosystem together within a single Clinical Research Information System (CRIS)
It integrates:
KEY CAPABILITIES
Key capabilities for hematology trials
Flexible study design for evolving hematology research
- Supports hematology study designs where treatment pathways, response criteria, and follow‑up schedules may change as evidence emerges
- Enables rapid configuration when dosing rules, cohorts, or endpoints are adjusted due to safety findings or changes in standard of care
- Allows updates without interrupting ongoing studies, helping teams manage protocol amendments common in long‑running hematology trials
Longitudinal data capture and consistency
- Supports frequent, repeat data collection across lab values, safety checks, clinical outcomes, and patient‑reported measures
- Unifies data flow across EDC, CTMS, RTSM, ePRO/eCOA, eTMF, eSource, and eConsent within a single CRIS
- Reduces manual reconciliation and data discrepancies across extended study timelines and multiple assessment points
Patient participation across intensive treatment schedules
- Flexible ePRO/eCOA to capture disease‑specific symptoms, treatment side effects, and quality‑of‑life changes over time
- Supports both remote and on‑site data capture for patients undergoing frequent visits, transfusions, or monitoring
- Automated reminders help sites and patients keep up with recurring assessments and long‑term follow‑up requirements
Safety oversight and study visibility
- Real‑time dashboards combining clinical data, laboratory results, and safety signals into a single view
- Supports ongoing safety review and interim decision‑making in studies with high monitoring intensity
- Provides export‑ready outputs to support regulatory submissions and inspections across FDA, EMA, and global authorities
Laboratory and specialty data integration
- Integrates data from central and specialty laboratories, including hematology panels, biomarkers, and genetic testing
- Connects lab and safety data directly to analytics and oversight workflows
- Provides a consolidated view of treatment response, safety outcomes, and longitudinal disease progression
Designed for hematology studies with frequent monitoring, complex lab data, and long‑term follow‑up requirements
Built on a single, unified CRIS foundation, avoiding the risk and overhead of stitching together multiple point systems
Allows study changes through configuration, so dosing rules, endpoints, and assessments can evolve without rebuilding the platform
Reduces operational strain for specialist sites, sponsors, and CROs managing intensive visit schedules and safety oversight
Replaces fragmented tools with one connected environment, improving data consistency and study visibility over time
VALUE PROPOSITION
Why sponsors choose oomnia for hematology trials
REGULATORY READINESS
Regulatory and data ecosystem readiness for hematology trials
oomnia provides hematology teams with inspection‑ready data environment built to support frequent safety monitoring, longitudinal data collection, and global regulatory requirements
21 CFR Part 11 compliance
21 CFR Part 11–compliant electronic records with full audit trails and secure electronic signatures
Risk-Based Quality Management
Risk‑Based Quality Management (ICH E6(R3)) integrated into daily trial operations, helping teams focus oversight on critical safety and data risks
CDISC-aligned data standards
Standards aligned data structures (e.g. CDISC), supporting CDASH‑based data capture and SDTM‑compatible outputs suitable for hematology submissions
Global regulatory support
Designed to support regulatory interactions and submissions worldwide, including FDA, EMA, and other health authorities
Get Started
Managing frequent labs, long follow‑up, and evolving protocols?
See how oomnia helps hematology teams keep data, workflows, and oversight aligned from study start to close
Talk to our team